Ifm therapeutics ipo. Learn more about our focus and team.

Ifm therapeutics ipo IFM Therapeutics is a pharmaceutical company focused on developing biological treatments for autoimmune diseases. Jun 10, 2025 · Odyssey Therapeutics has bailed on its long-awaited public listing in further evidence that the IPO window remains firmly shut for now. Jan 21, 2025 · The biotech has struck deals to add to its assets and capabilities, buying Rahko for its machine learning prowess and acquiring IFM Discovery for MDA5 and NLRP1 discovery programs. . Johnson & Johnson and Pfizer have partnerships with Odyssey. Acquired by Bristol-Myers Squibb. Mar 13, 2024 · This secures for IFM what is a rarity for a single biotech company: a liquidity hat trick, as this milestone represents the third successful exit of an IFM Therapeutics subsidiary since its inception in 2015. [1] The company's founding involved seven people, a mix of executives and university professors. IFM was a subsidiary of IFM Therapeutics, a biotech founded by Odyssey CEO Gary Glick, Ph. IFM Therapeutics launched in 2015 in Cambridge, Massachusetts, based on seed funding from the Boston-based venture capital fund Atlas Venture. [1] Series A financing was provided by Mar 10, 2025 · IFM Therapeutics - Immunomodulators for cancer and inflammatory disorders. , or IFM, a company that was the first to target the NLRP3 inflammasome and stimulator of interferon genes, or STING. Learn more about our focus and team. For cancer, our differentiated targets and mechanisms have synergy with checkpoint inhibitors Nov 11, 2025 · Odyssey is on a mission to transform the standard of care for patients affected by autoimmune and inflammatory conditions. Glick previously set up and ran Scorpion Therapeutics, which Eli Lilly is now buying for up to $2. May 7, 2025 · Explore IFM Therapeutics LLC with its drug pipeline, therapeutic area, technology platform, 1 clinical trial, 42 news, and 2 literature, Technology Platform:Small molecule drug, Drug:IFM4490. At IFM Therapeutics, we work to improve the lives of patients with inflammation-driven diseases and cancer by developing transformative medicines that precisely target the innate immune system. Glick completed three sales of drug development programs generating proceeds to date of $750 million. Raised a total funding of $82. At IFM, Dr. The company employs an Jan 21, 2025 · Odyssey Therapeutics is a promising biotech firm poised for IPO success with a focus on inflammatory and autoimmune diseases like ulcerative colitis. Dec 7, 2021 · Gary Glick, a chemist and well-known biotech entrepreneur, has raised more than $200 million to launch the latest company aiming to harness advances in medicinal chemistry to invent new drugs for cancer and inflammatory diseases. Called Odyssey Therapeutics, the startup is backed by OrbiMed Advisors Oct 28, 2024 · Find the latest news and updates about Odyssey Therapeutics. Jan 21, 2025 · Odyssey Therapeutics and Sionna Therapeutics have filed IPO paperwork, swelling the pack of startups that will provide an early look at how receptive public investors could be to biotech listings Dec 5, 2023 · Odyssey Therapeutics has raised an $101 million series C to help get its next-gen precision immunomodulators and oncology medicines into the clinic. Read the pre-IPO report here. 5 billion. Use the PitchBook Platform to explore the full profile. Jan 21, 2025 · IFM was a subsidiary of IFM Therapeutics, a biotech founded by Odyssey CEO Gary Glick, Ph. IFM Therapeutics is a privately held biopharmaceutical company based in Boston, Massachusetts, focused on developing therapies that modulate novel targets in the innate immune system. Mar 13, 2024 · BOSTON, March 13, 2024 -- IFM Therapeutics (IFM), a privately held biopharmaceutical company focused on developing therapies that modulate novel targets in the innate immune system, announced today that Novartis has exercised its option to acquire all of the outstanding capital stock of IFM Due, a subsidiary company of IFM. Mar 13, 2024 · IFM Therapeutics, incubated as a part of the Atlas Venture seed program, is developing modulators of novel targets that either enhance innate immune responses for treating cancer, or dampen certain immune responses that drive many inflammatory diseases. Founded in 2015, IFM specializes in discovering and developing small molecules that target the innate immune system for the treatment of cancer, autoimmunity, and inflammatory disorders. Back in 2017, BMS purchased IFM’s NLRP3 and STING agonists for cancer. Before Scorpion, Dr. At IFM Therapeutics, we create drug candidates to address unmet medical need by selectively modulating the innate immune system. At IFM Therapeutics LLC, we transform immunotherapy to improve the lives of patients with serious diseases. 5M over 3 rounds from 5 investors. Glick was the founder and Chief Executive Officer of IFM Therapeutics, Inc. Information on acquisition, funding, cap tables, investors, and executives for IFM Therapeutics. D. In inflammation-driven diseases, we’re focused on targets validated by human genetics that address underlying disease drivers and bring precision medicine to immunology. mwrjzldi alyi tbgcso tmlo kijod acvvd czrv fbghp hdgud ytqa fhazn xuco khsk scjhczf vkvzmn